Alkem Labs declares interim dividend of ₹43 per share; Q3 FY26 results announced
Alkem Laboratories declared an interim dividend of ₹43 per share for FY26, payable from March 6, 2026. The record date is February 20, 2026. The company also announced its financial results for the quarter and nine months ended December 31, 2025.
The dividend declaration directly benefits shareholders, while the financial results provide an update on the company's performance.
The declaration of an interim dividend and the approval of financial results are positive developments for shareholders.
Alkem Laboratories Limited announced the outcome of its Board Meeting held on February 13, 2026. The Board approved the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2025.
An interim dividend of ₹43 per equity share (on a face value of ₹2 per share) has been declared for the financial year 2025-2026. The payment date for this interim dividend is scheduled for March 6, 2026. The record date for the dividend payment is February 20, 2026.
The financial results for the nine months ended December 31, 2025, reflect an exceptional item of ₹527.9 million related to the impact of the new Labour Codes and a gain of ₹142.9 million from the sale of the Indore manufacturing facility.
The Board meeting commenced at 11:00 a.m. and concluded at 01:45 p.m.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.